ORIGINAL RESEARCH article
Front. Bioeng. Biotechnol.
Sec. Biomaterials
Volume 13 - 2025 | doi: 10.3389/fbioe.2025.1661383
In vitro evaluation of methylglyoxal as an antibacterial additive to bone cement
Provisionally accepted
- University of Veterinary Medicine Hannover, Hanover, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Periprosthetic joint infections (PJIs) are severe complications following surgical joint replacement and one of the main reasons for implant failure in human and veterinary medicine. Due to the global rise in antibiotic resistances and failure to prevent and treat PJIs, it is necessary to identify new antibacterial substances for the management of these infections. Methylglyoxal (MGO) is a dicarbonyl compound that has been identified as the main antibacterial component in Manuka honey. The aim of the study was to evaluate the suitability of MGO as an additive to polymethylmethacrylate bone cement in connection to PJIs. To test the antibacterial activity of pure MGO and MGO-containing bone cement against clinical isolates of Staphylococcus (S.) pseudintermedius, minimal inhibitory concentrations (MICs) were determined, growth of bacteria on bone cement was visualized, and the influence on infection of human osteosarcoma (HOS) cells was examined. Cytotoxicity of pure MGO and MGO-containing bone cement against HOS cells was analyzed with viability and proliferation assays, staining of cells on bone cement surface, and measurement of Interleukin-6 (IL-6) release. Activation of p38 MAP kinase was analyzed using western blotting. MGO inhibited growth of S. pseudintermedius at 0.15 mg/mL, reduced bacterial colonization of bone cement at 25 mg per bone cement platelet, and reduced infection of HOS cells at 0.05 mg/mL. The IC50 of pure MGO for cell viability was 0.17 mg/mL. At higher concentrations, bone cement with MGO reduced viability and proliferation, but did not cause IL-6 release. Western blots revealed p38 activation following MGO treatment, indicating involvement of the p38 pathway in stress reactions due to the treatment. Taken together, effectiveness of MGO against PJI-relevant S. pseudintermedius could be shown but biocompatibility was limited and further research is necessary to enhance biocompatibility.
Keywords: methylglyoxal, Periprosthetic joint infections, Bone cement, Antibacterial, Biocompatibility
Received: 07 Jul 2025; Accepted: 27 Aug 2025.
Copyright: © 2025 Bohn, Oltmanns and Meißner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jessica Meißner, University of Veterinary Medicine Hannover, Hanover, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.